The first evidences were obtained in breast cancer with abemaciclib, suggesting that suppression of the Rb–E2F axis leads to a reduced expression of the methyl-transferase DNMT1 and, thus, to the hypomethylation of genes that regulate the immune response. This evidence concerns the gene RB1 and breast carcinoma.